Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of a safety and efficacy analysis

被引：0
|
作者：
Arkenau, HT
Schmoll, H
Kubicka, S
Kretzschmar, A
Freier, W
Seufferlein, T
Graeven, U
Grothey, A
Hinke, A
Porschen, R
机构：
[1] Clin Bremen E, Clin Internal Med, Bremen, Germany
[2] Univ Halle Wittenberg, Halle Saale, Germany
[3] Hannover Med Sch, D-3000 Hannover, Germany
[4] Charite, Berlin, Germany
[5] Private Oncol Clin, Hildesheim, Germany
[6] Univ Ulm, Med Clin, Ulm, Germany
[7] Hosp Maria Hilf, Monchengladbach, Germany
[8] Mayo Clin, Rochester, MN USA
[9] Res Inst WISP Langenfeld, Res Inst WISP, Langenfeld, Germany
[10] Clin Bremen E 10, Bremen, Germany
来源：
ANNALS OF ONCOLOGY | 2005年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：283 / 283
页数：1
相关论文
共 50 条
  • [31] A phase II trial of second-line irinotecan and capecitabine after failure of first line infusional 5-fluorouracil and folinic acid in metastatic colorectal cancer (MCRC).
    Willer, AM
    Hofheinz, RD
    Wein, A
    Gnad-Vogt, U
    Saussele, S
    Hehlmann, R
    Hochhaus, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 307S - 307S
  • [32] Utilization of capecitabine-oxaliplatin (CAPOX) versus infusional 5-fluorouracil and oxaliplatin (FFOX) in the adjuvant treatment (AT) of resected high-risk colon cancer.
    Sha, Aaron
    Abadi, Shirin
    Gill, Sharlene
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Phase II study of capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal carcinoma
    Xu, R.
    Li, Y.
    Luo, H.
    Wang, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer.: EORTC study 40015
    Koehne, C.-H.
    De Greve, J.
    Hartmann, J. T.
    Lang, I.
    Vergauwe, P.
    Becker, K.
    Braumann, D.
    Joosens, E.
    Mueller, L.
    Janssens, J.
    Bokemeyer, C.
    Reimer, P.
    Link, H.
    Spath-Schwalbe, E.
    Wilke, H. -J.
    Bleiberg, H.
    Van den Brande, J.
    Debois, M.
    Bethe, U.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 920 - 926
  • [35] (XELOX) capecitabine plus oxaliplatin: Clinical efficacy and safety in the first-line treatment for metastatic gastric cancer
    Manuguerra, G.
    Alu, M.
    Leonardi, V.
    Laudani, A.
    Palmisano, V.
    Pepe, A.
    Arcuri, C.
    Savio, G.
    Cusimano, M.
    Calabria, C.
    Porretto, C.
    de Bella, M. Tamburo
    Agostara, B.
    ANNALS OF ONCOLOGY, 2007, 18 : 5 - 5
  • [36] (XELOX)Capecitabine plus Oxaliplatin: clinical efficacy and safety in first-line treatment for metastatic gastric cancer
    Alu, M.
    Laudani, A.
    Leonardi, V.
    Palmisano, V.
    Savio, G.
    Pepe, A.
    Arcuri, C.
    Cusimano, M. R.
    Calabria, C.
    Agostara, B.
    EJC SUPPLEMENTS, 2007, 5 (04): : 273 - 273
  • [37] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
    Seung Tae Kim
    Yong Sang Hong
    Ho Yeong Lim
    Jeeyun Lee
    Tae Won Kim
    Kyu-Pyo Kim
    Sun Young Kim
    Ji Yeon Baek
    Jee Hyun Kim
    Keun-Wook Lee
    Ik-Joo Chung
    Sang-Hee Cho
    Kyung Hee Lee
    Sang Joon Shin
    Hye Jin Kang
    Dong Bok Shin
    Jae Won Lee
    Sook Jung Jo
    Young Suk Park
    BMC Cancer, 14
  • [38] S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
    Kim, Seung Tae
    Hong, Yong Sang
    Lim, Ho Yeong
    Lee, Jeeyun
    Kim, Tae Won
    Kim, Kyu-Pyo
    Kim, Sun Young
    Baek, Ji Yeon
    Kim, Jee Hyun
    Lee, Keun-Wook
    Chung, Ik-Joo
    Cho, Sang-Hee
    Lee, Kyung Hee
    Shin, Sang Joon
    Kang, Hye Jin
    Shin, Dong Bok
    Lee, Jae Won
    Jo, Sook Jung
    Park, Young Suk
    BMC CANCER, 2014, 14
  • [39] Analysis of bi-weekly oxaliplatin plus folinic acid (FA)+5-fluorouracil (FU) in metastatic gastrointestinal (GI) carcinoma.
    Salinas, P
    Amador, ML
    Ciruelos, E
    Bezares, S
    Castellano, D
    Grávalos, C
    Hitt, R
    Cortes-Funes, H
    ANNALS OF ONCOLOGY, 2000, 11 : 50 - 50
  • [40] Biweekly oxaliplatin plus capecitabine (OXXEL) versus oxaliplatin plus folinic acid-modulated 5-fluorouracil i.v. bolus (OXAFAFU) in metastatic colorectal carcinoma (MCC): Safety interim analysis of a Southern Italy Cooperative Oncology Group (SICOG) phase III trial.
    Sandomenico, C.
    Filippelli, G.
    Massidda, B.
    Farris, A.
    Natale, D.
    Palmeri, S.
    Maiorino, L.
    Condemi, G.
    Leo, S.
    Greco, E.
    Gambardella, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 168S - 168S
12345